focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,973.00
Bid: 1,969.00
Ask: 1,970.00
Change: -5.00 (-0.25%)
Spread: 1.00 (0.051%)
Open: 1,984.00
High: 1,984.00
Low: 1,962.00
Prev. Close: 1,978.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 08th Jul 2013 08:48

Anglo American: Exane reduces target price from 1700p to 1400p and reiterates its underperform rating.Anite Group: Investec raises target price from 135p to 155p and upgrades from hold to buy.Ashmore Group: RBC Capital Markets takes target price from 440p to 375p and keeps its neutral rating.Balfour Beatty: Bank of America cuts target price from 255p to 240p and downgrades to neutral.Bovis Homes Group: Jefferies ups target price from 897p to 909p keeping a buy recommendation. Panmure Gordon raises target price from 660p to 714p and retains a hold recommendation.Escher Group: Panmure Gordon moves target price from 459p to 465p reiterating a buy recommendation.Fidessa: Sanlam Securities increases target price from 2000p to 2340p and stays with a buy recommendation.Hikma Pharmaceuticals: HSBC Holdings raises target price from 745p to 1035p, while retaining a neutral rating. Panmure Gordon takes target price from 1000p to 1100p and leaves its buy recommendation unaltered.Interserve: Westhouse Securities ups target price from 537p to 582p keeping an add rating.Investec: Morgan Stanley lowers target price from 525p to 500p and maintains an overweight rating.Petropavlovsk: Goldman Sachs revises target price from 106p to 76p and keeps its sell recommendation.Polymetal International: HSBC Holdings reduces target price from 1000p to 620p, while leaving its overweight rating unchanged. Goldman Sachs cuts target price from 800p to 340p downgrading from neutral to sell.Polyus Gold International: Goldman Sachs moves target price from 230p to 210p leaving its neutral rating unaltered.Restaurant Group: JP Morgan increases target price from 525p to 565p and reiterates an overweight rating.Spirent Communications: Goldman Sachs shifts target price from 164p to 160p, but leaves its buy recommendation unchanged.Synergy Health: Investec downgrades from buy to add with a target price of 1170p.Vodafone: Credit Suisse moves target price from 180p to 195p and retains an outperform rating.Young & Co's Brewery: JP Morgan takes target price from 840p to 910p and stays with its overweight rating.
More News
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more
4 Nov 2021 09:03

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

Read more
4 Nov 2021 07:58

Hikma reports solid trading in year to date

(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.

Read more
1 Nov 2021 13:52

Citi sees room for upside surprise on sales at Hikma Pharmaceuticals

(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.

Read more
28 Oct 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Oct 2021 09:51

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

Read more
27 Sep 2021 12:14

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.